Anthony G. Quinn, Interim CEO at Aeglea BioTherapeutics, Inc. (AGLE), bought 8,288 shares at $4.92 ($41K) on 2017-12-06, disclosed to the SEC on 2017-12-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.92 | 4,888 | $24K | 58.6% |
| 2 | $4.99 | 2,800 | $14K | 34.0% |
| 3 | $5.07 | 600 | $3K | 7.4% |
| Total | $4.95 avg | 8,288 | $41K | 100% |
| Filing → |
| AGLE | BUY | 2022-03-18 | $375K | — | Filing → |
| AGLE | BUY | 2022-03-15 | $562K | — | Filing → |
| AGLE | BUY | 2021-12-13 | $358K | — | Filing → |